Canaccord Genuity Remains a Buy on Savara Inc

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on Savara Inc (NASDAQ: SVRA) today and set a price target of $25. The company’s shares opened today at $9.45.

Steadman said:

“We maintain our BUY rating and $25 PT on SVRA shares.”

According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -6.4% and a 32.9% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Cardiome Pharma Corp.

Savara Inc has an analyst consensus of Moderate Buy, with a price target consensus of $22.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $17.19 and a one-year low of $4.60. Currently, Savara Inc has an average volume of 147.5K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SVRA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.